The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia

Background: Previous studies have suggested that NPM1 mutations may be a marker for response to all-trans retinoic acid (ATRA) given as an adjunct to intensive chemotherapy in older patients with acute myeloid leukemia (AML). Patients and Methods: We examined the impact of the addition of ATRA among...

Descripción completa

Detalles Bibliográficos
Autores principales: Nazha, Aziz, Bueso-Ramos, Carlos, Estey, Eli, Faderl, Stefan, O’Brien, Susan, Fernandez, Michael H., Nguyen, Martin, Koller, Charles, Freireich, Emil, Beran, Miloslav, Pierce, Sherry, Keating, Michael, Cortes, Jorge, Kantarjian, Hagop, Ravandi, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764477/
https://www.ncbi.nlm.nih.gov/pubmed/24032106
http://dx.doi.org/10.3389/fonc.2013.00218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764477/
https://www.ncbi.nlm.nih.gov/pubmed/24032106
http://dx.doi.org/10.3389/fonc.2013.00218

Ejemplares similares